{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:15:01Z","timestamp":1793517301280,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23 NS105935-01"],"award-info":[{"award-number":["K23 NS105935-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI137080"],"award-info":[{"award-number":["R01AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01HD074944-01"],"award-info":[{"award-number":["1R01HD074944-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI102639"],"award-info":[{"award-number":["K23AI102639"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijid.2019.04.026","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T12:15:36Z","timestamp":1556626536000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis"],"prefix":"10.1016","volume":"84","author":[{"given":"Alyssa","family":"Mezochow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran T.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Zentner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvakumar","family":"Subbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-7814","authenticated-orcid":false,"given":"Christopher","family":"Vinnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2019.04.026_bib0005","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMc1602291","article-title":"Therapy for tuberculous meningitis","volume":"374","author":"Boeree","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2019.04.026_bib0010","article-title":"Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR"},{"key":"10.1016\/j.ijid.2019.04.026_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01830-15","article-title":"Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of heaptic extraction","volume":"60","author":"Chirehwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"November","key":"10.1016\/j.ijid.2019.04.026_bib0020","article-title":"Intensified antibiotic treatment of tuberculous meningitis","author":"Cresswell","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijid.2019.04.026_bib0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1164\/arrd.1972.106.3.432","article-title":"Cerebrospinal fluid concentrations of rifampin in meningeal tuberculosis","volume":"106","author":"D\u2019Oliveira","year":"1972","journal-title":"Am Rev Respir Dis"},{"issue":"November (12)","key":"10.1016\/j.ijid.2019.04.026_bib0030","article-title":"Double-blind, randomized, placebo-controlled phase ii dose-finding study to evaluate high-dose rifampin for tuberculous meningitis","volume":"62","author":"Dian","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ijid.2019.04.026_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe1511990","article-title":"Chemotherapy for tuberculous meningitis","volume":"374","author":"Donald","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2019.04.026_bib0040","first-page":"4487","article-title":"Prognostic factors of tuberculous meningitis: a single-center study","volume":"8","author":"Gu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ijid.2019.04.026_bib0045","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2019.04.026_bib0055","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/clpt.1991.2","article-title":"Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis","volume":"49","author":"Kaojarern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2019.04.026_bib0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/phar.1388","article-title":"Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and the induction of efavirenz clearance","volume":"34","author":"Kwara","year":"2014","journal-title":"Pharmacother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/cid\/cis303","article-title":"Site of extrapulmonary tuberculosis is associated with HIV infection","volume":"55","author":"Leeds","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2019.04.026_bib0075","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/29.6.719","article-title":"Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges","volume":"29","author":"Nau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-199835030-00005","article-title":"Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections","volume":"35","author":"Nau","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2019.04.026_bib0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00042-07","article-title":"Central nervous system tuberculosis: pathogenesis and clinical aspects","volume":"21","author":"Rock","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2019.04.026_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2019.04.026_bib0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2174\/13816128113199990463","article-title":"Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?","volume":"20","author":"Sanchez-Covarrubias","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijid.2019.04.026_bib0100","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijid.2019.04.026_bib0105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/jac\/dkp262","article-title":"Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis","volume":"64","author":"Sch\u00f6n","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0110","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.addr.2004.07.011","article-title":"Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics","volume":"56","author":"Shen","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijid.2019.04.026_bib0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1471-4159.2009.06451.x","article-title":"Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress","volume":"112","author":"Spector","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.ijid.2019.04.026_bib0120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000358219","article-title":"The association between blood-cerebrospinal fluid barrier dysfunction and the therapeutic effect in tuberculous meningitis patients","volume":"71","author":"Tang","year":"2014","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ijid.2019.04.026_bib0125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2014.12.027","article-title":"Pharmacokinetic\/pharmacodynamics analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis","volume":"45","author":"te Brake","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2019.04.026_bib0130","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1128\/AAC.00319-12","article-title":"Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis","volume":"56","author":"Tho","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0135","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1474-4422(13)70168-6","article-title":"Tuberculous meningitis: more questions, still too few answers","volume":"12","author":"Thwaites","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ijid.2019.04.026_bib0140","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2008-1353","article-title":"Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa","volume":"123","author":"van Well","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2019.04.026_bib0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jinf.2011.07.005","article-title":"Multidrug resistant tuberculous meningitis in the United States, 1993-2005","volume":"63","author":"Vinnard","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2019.04.026_bib0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","article-title":"The long term mortality of tuberculosis meningitis in New York City","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2019.04.026_bib0155","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.04.026_bib0160","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1086\/598975","article-title":"Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance","volume":"48","author":"Weinstein","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2019.04.026_bib0165","series-title":"Guidelines for treatment of tuberculosis","author":"World Health Organization","year":"2010"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219301973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219301973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:11:15Z","timestamp":1778519475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219301973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"alternative-id":["S1201971219301973"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.04.026","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}